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Effects of weight loss on a low-carbohydrate diet on flow-mediated
dilatation, adhesion molecules and adiponectin
Jennifer B. Keogh*, Grant D. Brinkworth and Peter M. Clifton
CSIRO Human Nutrition, PO Box 10041 BC, Adelaide SA 5000, Australia
(Received 17 January 2006 – Revised 9 March 2007 – Accepted 21 March 2007)
Our aim was to determine whether short-term weight loss on a low-carbohydrate/low-saturated fat diet improved endothelial function compared
with a conventional high-carbohydrate diet, as this diet is expected to lower both blood glucose and LDL-cholesterol. In a randomised parallel
design of two energy-restricted diets in an outpatient setting, thirty-six subjects (BMI 33 (SEM 4) kg/m2) were randomised to a low- or high-carbo-
hydrate diet both low in saturated fat. Flow-mediated dilatation (FMD), fasting glucose, insulin, lipids, adiponectin and adhesion molecules were
measured at baseline, during weight loss and at 52 weeks. FMD did not change with either diet (5·2 (SEM 0·6) to 5·5 (SEM 0·6) %) despite weight
loss of 5 % and significant reductions in glucose and insulin and LDL-cholesterol and was not different after sustained weight loss of 5 % at 52
weeks. Adiponectin fell by 6 % at 12 weeks (P¼0·1) with weight loss but rose by 17 % at 12 months (P,0·05) with 5 % weight loss. There were
no effects of diet. In contradistinction, adhesion molecules fell at 12 weeks, vascular cell adhesion molecule-1 by 14 % and intracellular adhesion
molecule-1 by 13 % (both P,0·05). There were correlations between change in adiponectin at 12 months and change in HDL (r 0·778, P,0·01)
and glucose (r 2 0·563, P¼0·057). In summary, weight loss does not improve FMD. Novel cardiovascular risk factors improved at 12 weeks but
the improvement in adiponectin was delayed.
Endothelium: Weight loss: Low-carbohydrate diet: Flow-mediated dilatation: Adhesion molecules
Obesity is associated with impaired endothelial function
assessed by flow-mediated dilatation (FMD)1 but the
evidence that weight loss improves FMD is contradictory.
There are several studies showing that reductions in
LDL-cholesterol (LDL-C) and fasting glucose concen-
trations but not weight loss per se were associated with
improvements in FMD2,3. The effect on FMD of dietary
composition has not been extensively examined and has
largely focused on the effect of dietary fat on FMD in a
weight-stable setting4 – 7. To our knowledge there is only
one study of the effect of a low-carbohydrate diet on
endothelial function during weight loss and this was
conducted using a very-low-caloric diet3. Weight loss
per se is usually associated with reductions in LDL-C8
and reducing saturated fat also decreases LDL-C9. We
therefore developed a diet low in saturated fat and low
in carbohydrate to maximise LDL-C reduction and reduce
glucose concentrations designed to achieve moderate
weight loss in order to test whether the combined effects
with weight loss would improve FMD.
Obesity is independently associated with increased levels of
cellular adhesion molecules and weight loss has been shown to
reduce them10,11. There are few studies of the effect of diet on
adhesion molecules and these have examined dietary fat12,13.
Adiponectin is an insulin sensitising agent which is reduced
in obesity14,15. It has been shown to increase after large
amounts of weight loss after gastroplasty for morbid obesity
and after weight loss in subjects with diabetes but not after
moderate weight loss in a short-term loss programme in
non-diabetic women16 – 19. Macronutrient composition may
also have an effect on adiponectin. Kasim-Karakas et al.20
observed a reduction in adiponectin on a eucaloric low-fat
diet which returned to baseline after 6 kg weight loss on a
low-fat diet but overall there was no improvement in
adiponectin levels.
The aim of the present study therefore was to examine the
effect of a low-carbohydrate compared to a conventional high-
carbohydrate diet on endothelial function as assessed by FMD
and levels of adhesion molecules, and adiponectin after short-
term weight loss with long-term follow-up.
We hypothesised that a low-carbohydrate weight-loss diet
in comparison with a conventional high-carbohydrate, low-
fat diet would be associated with improvements in FMD and
adiponectin.
*Corresponding author: Ms Jennifer Keogh, fax þ61 (0)8 83038899, email jennifer.keogh@csiro.au
Abbreviations: CRP, C-reactive protein; FMD, flow-mediated dilatation; HC, high-carbohydrate diet; HDL-C, HDL-cholesterol; LC, low-carbohydrate diet; LDL-C,
LDL-cholesterol; sICAM1, soluble intracellular adhesion molecule-1; sVCAM-1, soluble vascular cell adhesion molecule-1; VCAM-1, vascular cell adhesion
molecule-1.
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Study design and subjects
Subjects (101) were recruited by newspaper advertisement.
Inclusion criteria were age 20–65 years and BMI 27–40 kg/
m2. Exclusion criteria were diabetes mellitus or fasting
glucose .7·0 mmol/l, resting blood pressure .150/
95 mmHg, medications affecting study measurements, active
liver or kidney disease or malignancy, current gastrointestinal
disease, pregnancy or lactation, and more than 50 g alcohol/d.
The study protocol was approved by the Human Ethics
Committee of the Commonwealth Scientific Industrial
Research Organisation (CSIRO) and subjects provided
informed written consent. The trial was registered with the
Australian Clinical Trials Registry (N012605000614695).
Forty-four subjects were selected and matched for age,
gender and BMI; seven withdrew before the study commenced
for personal reasons. Twenty-five subjects (seventeen female,
eight male; mean age 48·7 (SEM 1·5) years, weight 94·2 (SEM
3·5) kg, BMI 32·9 (SEM 0·9) kg/m2, glucose 5·9 (SEM 0·1)
mmol/l, insulin 14·8 (SEM 2·2) mIU/l) completed the active
weight-loss part of the study (12 weeks; Table 1). Two
subjects were lost to follow-up, seven withdrew for personal
reasons, two were unable to comply with the protocol and
one withdrew for medical reasons unrelated to the study.
Thirteen subjects attended for final assessments at 52 weeks.
Dietary methodology
In a randomised parallel design subjects were allocated to a
weight-loss diet that was either low carbohydrate (LC;
,33 % energy as carbohydrate, 27 % energy as fat, 40 %
energy as protein, 7 % energy from saturated fat, 6 % energy
from PUFA and 13 % energy from MUFA and 26 g fibre) or
high carbohydrate (HC), low fat (,20 % energy as fat, 20 %
energy as protein and 60 % energy as carbohydrate, 4 %
energy from saturated fat, 5 % from PUFA and 7 % from
MUFA and 40 g fibre). Both diets were designed to be
,6000 kJ so that weight loss would approximate 0·5–1 kg
per week. Records of daily food intake were maintained in
order to monitor food intake and volunteers saw a dietitian
individually at the start of weight loss and every 2 weeks.
Volunteers attended the CSIRO clinic monthly during
follow-up for a consultation with the same qualified dietitian.
The dietary data were analysed using FoodWorks version 3.1
dietary analysis software (Xyris Software, Highgate Hill,
Australia). In order to ensure that the energy restriction was
approximately 30 % below estimated usual intake a FFQ
was completed at baseline to assess usual energy and nutrient
intake21 (Table 1).
Weight and height
Fasting body weight (Mercury digital scales, model AMZ14,
Tokyo, Japan) was recorded in light clothing without shoes
at baseline and every 2 weeks during weight loss and monthly
during follow-up. Height was measured on a stadiometer
(Seca, Hamburg, Germany) at baseline. BMI was calculated
by weight (kg)/height (m2).
Resting (seated) blood pressure
Resting blood pressure (mean of three measurements) was
measured by automated oscillometry (845XT/XT-IEC, Dina-
mape, Tampa, FL, USA) with subjects in a seated position
for 5 min at baseline and every 4 weeks and also at 6 weeks
after the start of weight loss when FMD was measured.
Flow-mediated dilatation
Subjects underwent assessment of endothelium-dependent
FMD of the right brachial artery, as previously described22,
at baseline, after 6 weeks of intensive weight loss when diet-
ary adherence would be at its best and glucose and LDL-C
were predicted to be at their lowest level, and at 52 weeks.
Subjects were kept quiet for 5 min before vessel diameter
measurements which were taken in the morning after an over-
night fast, using a 7·5 MHz linear array transducer of an
Acuson Aspen ultrasound (Siemens, Denver, CO, USA)
before and after forearm ischaemia caused by inflation of a
blood pressure cuff, which had been placed around the
subjects’ forearm approximately 2 cm distal to the olecranon,
to 200 mmHg for 5 min. Measurements were also recorded for
4 min at 15 s intervals after a 300mg tablet of nitro-glycerine
was administered sublingually. The operator performing the
FMD procedure was blind to the dietary treatment. All FMD
measurements were evaluable and none were repeated.
Measurements were also recorded for 4 min at 15 s intervals
after a 300mg tablet of nitro-glycerine was administered
sublingually. Based on assessments performed on two separate
days in nine subjects by the operator, the within-subject CV of
the endothelium-dependent response was 8·4 %.
Pulse wave velocity
Aortic pulse wave velocity was measured via doppler record-
ings at the carotid and femoral arteries at baseline, 6, 12 and
52 weeks. Approximately ten consecutive beats were recorded
to cover a complete respiratory cycle. A simultaneous
Table 1. Baseline characteristics of subjects
Low-carbo-
hydrate diet (n 13)
High-carbo-
hydrate diet (n 12)
Mean SEM Mean SEM
Age (years) 50·1 1·4 46·9 1·6
BMI (kg/m2) 32·6 1·0 33·2 0·8.
Weight (kg) 91·5 4·1 97·6 2·4
Glucose (mmol/l) 5·9 0·2 5·8 0·2
Insulin (mIU/l) 16·9 2·8 12·1 1·2
Total cholesterol (mmol/l) 5·3 0·2 5·7 0·3
TAG (mmol/l) 1·7 0·2 1·4 0·1
HDL-cholesterol (mmol/l) 1·3 0·1 1·3 0·1
LDL-cholesterol (mmol/l) 3·5 0·2 3·8 0·3
SBP (mmHg) 122 3 122 3
DBP (mmHg) 75 1 75 1
Energy (MJ) 11·4 1·4 10·8 1·2
Protein (% energy) 19·6 0·7 19·3 0·9
Fat (% energy) 36·5 1·0 35·4 0·7
Carbohydrate (% energy) 39·6 1·2 40·2 1·0
Alcohol (% energy) 4·4 0·9 3·3 0·6
Fibre (g/d) 31 4 28 2
DBP, diastolic blood pressure; SBP, systolic blood pressure.

















electrocardiogram recording was used to calculate the interval
between the R-wave and the upstroke of each sound wave.
The difference between the average intervals for each artery
was calculated. Pulse wave velocity was then determined by
dividing the measured surface distance by this difference.
Measurement of Augmentation Index
Vascular measurements were performed as previously
described23 using the SphygmoCore blood pressure analysis
system (AtCor Medical, Sydney, Australia) at baseline, 6, 12
and 52 weeks.
Blood collections
At baseline, 6, 12 and 52 weeks subjects had fasting bloods for
the measurement of plasma glucose and insulin, serum total
cholesterol, TAG, HDL-cholesterol (HDL-C) and LDL-C. At
baseline, 12 and 52 weeks subjects had fasting blood samples
taken for high-sensitivity C-reactive protein (hs-CRP), vascu-
lar cell adhesion molecule-1 (VCAM1), soluble intracellular
adhesion molecule-1 (sICAM1), E-selectin, P-selectin and
total adiponectin.
Laboratory analysis
Total cholesterol, HDL-C, TAG and glucose were measured
using a Boehringer Mannheim/Hitachi 902 automatic analy-
ser (Boehringer Mannheim GmbH, Mannheim, Germany)
and LDL-C concentrations in serum were calculated using
the Friedwald equation [(total cholesterol 2 HDL-C) –
(TAG £ 0·45)]. High-sensitivity CRP concentrations were
measured using a Tina-quant C-reactive protein (latex) high-
sensitivity kit (Roche Diagnostics, Rotkreuz, Switzerland),
with 0·03 mg/l as the lowest detection limit and an interassay
CV of 10 %. Serum insulin was measured by AxSYM micro-
particle enzyme immunoassay, with 1·0 mIU/l as the lowest
limit of detection (Mercodia Insulin ELISA cat. no.
10-1113-10’ Mercodia AB, Uppsala, Sweden). Concentrations
of sICAM-1, sVCAM-1, E-selectin, P-selectin and adiponectin
were determined by an ELISA (ImmunoKontact, Wiesbaden,
Germany).
Statistics
ANOVA with repeated measures was used. All analyses were
performed using SPSS for Windows version 10.0 (SPSS Inc.,
Chicago, IL, USA) and statistical significance was set at
P,0·05. All values are means with their standard errors
unless otherwise stated.
Power
With twelve people in each group based on a CV for FMD of
10 %, we had sufficient power to measure a change of 12 % in
FMD with 80 % probability and a change of 14 % with 90 %
probability.
Results
Weight, body composition and waist circumference
When FMD was repeated at 6 weeks subjects had lost 6·1
(SEM 0·6) % (P,0·01) of their initial body weight with no
difference between diets. After 12 weeks they had lost 8·7
(SEM 0·7) % (P,0·01) (Table 2). Those volunteers who
remained in the study for 52 weeks (n 13) lost 5·6 (SEM 1·4)
% of their initial body weight with no difference between
diets (P,0·01) (Table 2).
Waist circumference was also significantly reduced after 12
weeks (and remained reduced at the end of study; P,0·01 for
time with no diet effect).
Dietary intake
Compliance with the protocol was confirmed by the dietary
analysis. Energy intake and percentage energy from saturated
fat were not different between the groups during the short-
term part of the study, 6262 (SEM 323) v. 6242 (SEM 352)
kJ, 7·4 (SEM 0·3) v. 3·7 (SEM 0·5), HP v. LC, respectively.
As planned, percentage energy from carbohydrate was stat-
istically different between the groups (37·7 (SEM 1·5) v. 53·4
(SEM 1·1) %, HP v. LC, respectively, P,0·001). Percentage
energy from protein (35·7 (SEM 1·1) v. 22·6 (SEM 0·7) %,
HP v. LC, respectively, P,0·001) and total fat were also
different (24·6 (SEM 0·8) v. 20·9 (SEM 1·0) %, HP v. LC,
respectively, P,0·01).
Flow-mediated dilatation
At baseline, brachial artery diameter before inflation of the
cuff was 4·53 (SEM 0·21) mm and 4·63 (SEM 0·28) mm, LC
and HC, respectively. There was an increase to 4·87 (SEM
0·21) mm and 4·8·4 (SEM 0·28) mm after the cuff was released,
Table 2. Anthropometric variables at 6 and 12 weeks (n 25) and 52 weeks (n 13)
(Mean values with their standard errors)
6 weeks 12 weeks 52 weeks
LC HC LC HC LC HC
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
Weight change (kg) 25·8** 3·1 25·9** 3·7 28·5** 4·5 27·9** 1·1 24·6** 2·1 25·5** 1·2
Waist circumference change (cm) NA NA 24·8** 1·3 26·4** 1·1 24·0** 1·6 27·0** 0·7
HC, high-carbohydrate diet; LC, low-carbohydrate diet; NA, not applicable.
Mean values were significantly different from those of the baseline: **P,0·01 (no diet effect).

















LC and HC, respectively (P,0·001). After weight loss neither
baseline nor post-ischaemic change in FMD were different,
45·8 (SEM 1·6) mm LC v. 46·1 (SEM 1·3) mm HC, increasing
to 48·1 (SEM 1·8) mm LC v. 48·3 (SEM 1·3) mm HC
(P,0·001), with no difference between the diet groups.
FMD did not change after weight loss of 6·1 (SEM 0·6) %
(Table 3). FMD was negatively correlated with age (r 2424,
P,0·05) but there was no correlation with any other variable
in particular lipid or glucose values.
FMD was not different from baseline after sustained weight
loss of 5·6 (SEM 1·4) % at the end of the study (Table 4).
Resting (seated) blood pressure
Resting systolic and diastolic blood pressure were both lower
after 6 weeks of weight loss (P,0·01) and remained reduced
at 12 weeks (P,0·01) with no further change and no differ-
ence between diets (Table 3). At the end of the study diastolic
blood pressure remained reduced but systolic blood pressure
was not different (Table 4).
Augmentation Index and pulse wave velocity
Augmentation Index, pulse wave velocity and arterial compli-
ance were not different compared to baseline at 12 (Table 3)
or 52 weeks (Table 4).
Glucose
There was a small but statistically significant reduction in
fasting glucose at 6 weeks (20·22 (SEM 0·08) mmol/l), with
no effect of diet (20·28 (SEM 0·09) v. 20·13 (SEM 0·08)
mmol/l LC v. HC, P,0·05)), which had rebounded somewhat
at 12 weeks (20·18 (SEM 0·09) mmol/l, P¼0·06; Table 5) but
there was no reduction at the end of the study (Table 6).
Insulin
Insulin was lower after 6 weeks of weight loss (22·87 (SEM
0·10) mIU/l, P,0·01, no diet effect) and was further reduced
at 12 weeks (24·43 (SEM 1·05) mIU/l, P,0·001; Table 5). At
the end of the study insulin remained reduced from baseline
(24·29 (SEM 1·12) mIU/l, P,0·001; Table 6).
Lipids
Total cholesterol fell at 6 weeks (20·88 (SEM 0·13) mmol/l,
P,0·01) with no difference between diets and remained
reduced at 12 weeks (20·81 (SEM 0·14) mmol/l, P,0·01;
Table 5) and at the end of the study (20·95 (SEM 0·28)
mmol/l, P,0·01; Table 6).
HDL-C fell from baseline at 6 weeks (20·10 (SEM 0·04)
mmol/l, P,0·05; Table 5) but was not different from baseline
after 12 or 52 weeks (Table 6).
LDL-C was lower at 6 weeks (20·63 (SEM 0·19) mmol/l,
P,0·01, no effect of diet) and remained reduced at 12
(20·71 (SEM 0·15) mmol/l, P,0·01) and 52 (20·95 (SEM
0·27) mmol/l, P,0·01) weeks (Tables 5 and 6).
TAG was reduced at 6 (20·33 (SEM 0·01) mmol/l, P,0·01)
and remained reduced at 12 weeks (20·44 (SEM 0·11) mmol/l,
P,0·01) with no effect of diet but was not reduced at the end
of the study (Tables 5 and 6).
Adhesion molecules: soluble intracellular adhesion molecule-
1, soluble vascular cell adhesion molecule-1, E-selectin and
P-selectin
There were reductions in sVCAM1 (P,0·05), sICAM
(P,0·05) and E-selectin (P,0·01) after weight loss with no
diet effect (Table 7), sICAM remained reduced at the end of
the study (P,0·05) whereas the change in sVCAM1 did not
reach statistical significance (P¼0·08; Table 5). E-selectin
remained reduced at the end of the study (P,0·05; Table
7). P-selectin did not change after 12 weeks of weight loss
but was reduced at the end of the study (P,0·05).
Adiponectin
Adiponectin did not change significantly after 12 weeks of
weight loss although it was lower than the initial level
(P¼0·1; Table 5) but it increased at the end of the study
(P,0·05). Adiponectin was negatively correlated with insulin
at baseline (r 2 0·485, P,0·05) but not at the end of the
study, while HDL was positively correlated at the start and
the end of the study (r 0·630, P,0·01, r 0·778, P,0·01,
respectively). Change in adiponectin was correlated with
change in insulin at the end of the study (r 0·552, P¼0·05)
and the correlation remained significant but was slightly
Table 3. Vascular measures at 0, 6 and 12 weeks (n 25)
(Mean values with their standard errors)
0 weeks 6 weeks 12 weeks
LC HC LC HC LC HC
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
FMD (%) 5·3 0·6 5·9 0·5 5·3 0·5 5·0 0·8 NA NA
SBP (mmHg) 122 4 123 4 110† 4 115** 4 111** 4 118** 5
DBP (mmHg) 74 2 76 2 68† 2 72** 1 67** 2 70** 2
AI (%) 27 2 20 4 27 2 24 3 27 2 22 3
PWV (m/s) 9·6 1·1 10·1 0·7 9·2 0·5 8·6 2·0 10·0 0·8 4·9 2·8
AI, Augmentation Index; DBP, diastolic blood pressure; FMD, flow-mediated dilatation; HC, high-carbohydrate diet; LC, low-carbohydrate diet; PWV, pulse wave
velocity; SBP, systolic blood pressure.
Mean values were significantly different from those of the baseline (0 weeks): **P,0·01; †P , 0·05.

















weaker after adjustment for baseline BMI (r 0·579, P,0·05).
Change in adiponectin was also correlated with change in
HDL (r 0·797, P,0·01, corrected for baseline BMI) nega-
tively with change glucose (r 2 0·617, P,0·05, corrected
for baseline BMI). Adiponectin was correlated with systolic
blood pressure at baseline (r 2 0·427, P,0·05) and 52
weeks (r 2 0·554, P,0·05) and with diastolic blood pressure
at 52 weeks (r 2 0·610, P,0·05) but not at baseline. There
were also trends towards negative correlations between
change in adiponectin and change in VCAM (r 2 0·524,
P¼0·08) and intracellular adhesion molecule-1 (ICAM;
r 2 0·570, P¼0·05).
C-reactive protein
CRP did not change after 12 weeks of weight loss or at the end
of the study and this remained true when subjects with
CRP . 10 mg/l were excluded from the analysis (Table 7).
Discussion
The main finding of the present study was that weight loss on
a low-carbohydrate diet which brought about reductions in
glucose, insulin and LDL-C did not improve FMD either
after short-term weight loss or long-term weight maintenance.
Irrespective of diet composition weight loss had beneficial
effects in the short term on adhesion molecules and blood
pressure and in the longer term on adiponectin and P-selectin.
There appears to be a delay in improvement in both adiponec-
tin and P-selectin as these molecules did not in improve until
weight loss had been maintained for a year.
Lack of change in FMD in the present study confirms our
previous findings that weight loss does not improve FMD24.
In our previous study FMD did not change with weight loss
of approximately 6 kg on two different low-fat diets, with
reductions in TAG, insulin, CRP, plasminogen activator
inhibitor-1 and sICAM1. Similarly to our results, Brook
et al.25 did not demonstrate improvement in FMD following
weight loss on orlistat with a reduction in LDL-C of approxi-
mately 7 % and weight loss of a similar amount.
However, these findings are in contrast to studies showing a
benefit on FMD of weight loss2,3,26,27. Differences between
the present study and other studies include an exercise
component and a much greater weight loss of 23 kg which
may also have had an impact on the improvement in
FMD26,27. Improvements in endothelial function, measured
as the blood flow responses to intra-arterial acetylcholine
have been observed following similar weight loss of 7 kg on
orlistat which correlated with a reduction in LDL-C3. One
of our goals with the dietary intervention was a reduction in
LDL-C which we achieved, 18 % at 6 weeks and nearly
30 % at the end of the study with no effect on FMD.
Table 4. Vascular measures at 0 and 52 weeks (n 13)
(Mean values with their standard errors)
0 weeks 52 weeks
LC HC LC HC
Mean SEM Mean SEM Mean SEM Mean SEM
FMD (%) 5·3 0·8 7·0 1·3 4·4 0·7 4·8 0·6
SBP (mmHg)† 117 4 128 3 115 5 130 4
DBP (mmHg) 72 2 80 2 68* 3 74* 3
AI (%) 26·5 3·7 21·0 5·2 24·4 2·2 22·3 4·7
PWV (m/s) 8·3 0·7 11·2 0·7 10·3 0·6 8·8 0·6
AI, Augmentation Index; DBP, diastolic blood pressure; FMD, flow-mediated dilatation; HC, high-carbohydrate
diet; LC, low-carbohydrate diet; PWV, pulse wave velocity; SBP, systolic blood pressure.
Mean values were significantly different from those of the baseline (0 weeks): *P,0·05.
† SBP was different by diet at baseline and at 52 weeks in the thirteen volunteers who participated in the study
until 52 weeks.
Table 5. Glucose, insulin and lipids at 0, 6 and 12 weeks (n 25)
(Mean values with their standard errors)
0 weeks 6 weeks 12 weeks
LC HC LC HC LC HC
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
Glucose (mmol/l) 5·90 0·81 5·83 0·41 5·44* 0·45 5·50* 0·52 5·52 0·42 5·48 0·48
Insulin (mU/ml) 16·88 13·89 11·84 6·08 9·53*** 6·08 6·73*** 3·09 7·97*** 5·12 8·96*** 5·44
Total cholesterol (mmol/l) 5·32 0·88 5·73 1·31 4·52** 0·84 4·78** 1·38 4·59** 0·87 4·82** 1·10
HDL-cholesterol (mmol/l) 1·26 0·31 1·33 0·31 1·12* 0·24 1·26* 0·33 1·23 0·28 1·34 0·31
LDL-cholesterol (mmol/l) 3·49 0·96 3·80 1·54 2·86** 0·76 3·01** 1·34 2·88** 0·80 2·98** 0·99
TAG (mmol/l) 1·72 0·87 1·39 0·59 1·20** 0·57 1·13** 0·52 1·06** 0·50 1·11** 0·61
HC, high-carbohydrate diet; LC, low-carbohydrate diet.
Mean values were significantly different from those of the baseline (0 weeks): *P,0·05; **P,0·01; ***P,0·001.

















Improvements in FMD which correlated with reductions in
fasting glucose of 8 % but not with weight loss per se or the
reduction in LDL-C have also been reported3. The present
study was also designed to achieve a reduction in glucose in
a 6-week weight-loss intervention on a more moderate diet
of 6000 kJ and we achieved this but with no effect on FMD.
It is unclear why these conflicting results occur. Different
study design and methods to assess endothelial function
make it difficult to compare the studies directly.
It is perplexing that in a large (n . 2000) longitudinal study
in young Finns there was a direct correlation between FMD
and BMI whereas most studies report that obesity is associated
with impaired FMD3,28 – 30. The authors suggest that an
increase in body size in the non-obese range is associated
with physiological changes resulting in enhanced FMD.
However, BMI is a surrogate measure of body fatness and
there are people for whom BMI is not an appropriate measure
of obesity and more direct measures of fat mass are
needed31,32.
We acknowledge that weight loss is an intervention that
leads to changes in many physiological systems but the
extent to which each system changes varies between indi-
viduals. A complex physiological response such as FMD
may be related to LDL and glucose cross-sectionally and
in post hoc analyses but these may not be causally related
but correlate in some circumstances with the real unmeas-
ured mediator of change. For instance, oxidative stress
may be a major factor in reducing NO bioactivity but
reducing LDL levels may have no effect on this even
though the endothelial cell is clearly healthier as judged
by reduced adhesion molecules.
Adiponectin rose at the end of the present study but not
after short-term weight loss. With weight loss of 5 kg
sustained at 12 months we observed a 16 % increase in adipo-
nectin, suggesting that it is sensitive to small amounts of
weight loss.
Several studies have examined the effect of weight loss on
adiponectin with conflicting results16 – 18,33. Adiponectin con-
centrations increased by approximately 28 % after large
amounts of weight loss over a long period (39 kg) while diet
and physical activity achieved 7 kg weight loss and an increase
in adiponectin in eight diabetic subjects but not in the group as
a whole16,17. Other studies found that adiponectin levels
increased in a rosiglitazone-treated group but not in a
weight loss-only group or that there was no improvement in
adiponectin after 7 kg of weight loss18,19. A low-fat diet in
energy balance has been shown to decrease adiponectin by
about 13 % while weight loss of 6 kg on a low-fat diet brought
adiponectin back to baseline but with no overall increase20.
Therefore adiponectin did not change in three short-term and
one longer-term study with moderate weight loss but increased
in two long-term studies, including our own suggesting that it
takes time for adiponectin production to adjust to weight loss.
We observed reductions in sVCAM1, sICAM and E-selec-
tin after short-term weight loss and sICAM, E-selectin and
P-selectin were reduced at the end of the study whereas
Table 6. Glucose, insulin and lipids at 0 and 52 weeks (n 13)
(Mean values with their standard errors)
0 weeks 52 weeks
LC HC LC HC
Mean SEM Mean SEM Mean SEM Mean SEM
Glucose (mmol/l) 5·37 0·07 5·57 0·09 5·19 0·13 5·50 0·09
Insulin (mU/ml) 11·06 2·64 9·09 0·78 7·28*** 1·50 5·22*** 0·49
Total cholesterol (mmol/l) 5·41 0·23 6·08 0·52 4·62** 0·25 4·94** 0·51
HDL-cholesterol (mmol/l) 1·33 0·08 1·30 0·08 1·44 0·14 1·34 0·07
LDL-cholesterol (mmol/l) 3·48 0·21 4·16 0·49 2·69 0·29† 3·01** 0·42
TAG (mmol/l) 1·35 0·08 1·38 0·18 1·07 0·08 1·34 0·27
HC, high-carbohydrate diet; LC, low-carbohydrate diet.
Mean values were significantly different from those of the baseline (0 weeks): **P,0·01; ***P,0·001; P , 0·05.
Table 7. Adhesion molecules soluble intracellular adhesion molecule-1 (sICAM), soluble vascular cell adhesion
molecule-1 (sVCAM), E-selectin, P-selectin, adiponectin and C-reactive protein (CRP) at 0 and 12 weeks (n 25) and 0
and 52 weeks (n 13)
(Mean values with their standard errors)
0 weeks 12 weeks 0 weeks 52 weeks
Mean SEM Mean SEM Mean SEM Mean SEM
sVCAM1 (ng/ml) 843 39 793* 33 778 40 726 185
sICAM (ng/ml) 340 20 294* 18 345 34 316* 42
E-selectin (ng/ml) 84 8 72** 7 79 11 71* 12
P-selectin (ng/ml) 166 15 169 22 150 16 127* 15
Adiponectin (ng/ml) 6992 684 6598 590 5983 742 7004* 993
CRP (mg/l) 3·57 1·0 3·76 1·38 1·87 0·3 2·44 0·6
Mean values were significantly different from those of the baseline (0 weeks): *P,0·05; **P,0·01.

















VCAM1 was not but this may be due to the small sample size.
This has also been observed by others10,34,35.
Limitations of the study
We estimated that for the short-term part of the study we had
sufficient power to measure a change of 12 % in FMD with
80 % probability. However, this is still a relatively small
study and we had a higher than anticipated dropout rate
during the follow-up, making the long-term results less
robust. The numbers of subjects are similar to the subject
numbers in other studies in which FMD improved with
weight loss (e.g. Hamdy et al.26, n 24; Vazquez et al.36,
n 26) but smaller that other studies (e.g. Raitakari et al.3,
n 67; Shechter et al.37, n 80). In one study the subject numbers
are smaller (n 6) than in the long-term part of the present
study, however weight loss, 23 kg, was much greater27.
We acknowledge that a relatively small sample size and
higher than anticipated dropout rate is a limitation of the
study.
In conclusion, weight loss on a low-carbohydrate, low-satu-
rated fat diet, does not improve FMD despite improvement in
cardiovascular risk factors. The improvement in adiponectin
was delayed.
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